Where Will DexCom Be in 5 Years?
Over the past five years, diabetes-focused medical device specialist (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose monitoring (CGM) niche and entered new geographies. Its revenue has generally increased at a good pace on a year-over-year basis.
However, after a recent plunge, DexCom has underperformed the S 500 in the past half-decade. Can DexCom turn things around? Let's see how things could evolve for the healthcare company through the next five years.
CGM technology, which allows diabetes patients to track their blood glucose levels efficiently throughout the day, has been linked with better outcomes. As clinical evidence has piled up, third-party payers have been more willing to cover CGM technology. However, the percentage of people using CGM continues to trail the population that is covered, even in the U.S. According to some estimates, about 2.4 million Americans use CGM monitors even though the covered population is about 7 million.
Source Fool.com
Dexcom Inc. Aktie
Die Community bevorzugt klar Dexcom Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Mit einem Kursziel von 75 € für Dexcom Inc. könnte eine leichte Steigerung gegenüber dem aktuellen Kurs von 73.4 € erreicht werden.
